XERS News and Press, Xeris Pharmaceuticals Inc. From 12/12/19

Of all the new science coming in through ASH 2019, one of the most important abstracts is this one from Roche (RHHBY). Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Recept...

All subjects successfully self-administered a mini dose of RTU glucagon Rebound hypoglycemia observed more frequently in the placebo arm and with oral glucose tablet use Subcutaneous RTU glucagon is safe and well-tolerated Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specia...

Xeris Pharmaceuticals (NASDAQ: XERS ) is up 5% in decent post-holiday volume after disclosing that Chairman/CEO Paul Edick bought 17,935 shares this week. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

MAA submitted to EMA of liquid stable glucagon for severe hypoglycemia GVOKE ™ PFS launch underway GVOKE HypoPen ™ expected to launch July 2020 CHI program shifts to Expanded Access HAAF program discontinued based on Phase 2 results CHICAGO, Nov. 21...

Xeris Pharmaceuticals (NASDAQ: XERS ): Q3 GAAP EPS of -$1.22 beats by $0.02 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription MAA for ready-to-use glucagon on track for submission to EMA by year-end Data from three Phase 2 studies expected by year-end CHICAGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceut...

The European advisory group CHMP has adopted a positive opinion recommending approval of Eli Lilly's (NYSE: LLY ) Baqsimi (glucagon) for severe hypoglycemia (low blood sugar). More news on: Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Zealand Pharma A/S, Healthcare stocks news, ...

CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, has appointed Mark Thierer to...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it began dosing patients in a Phase 2 clinical study to ev...

The FDA approves Xeris Pharmaceuticals' ( XERS +0.9% ) GVOKE (glucagon), a ready-to-use, room temperature-stable liquid glucagon for the treatment of severe hypoglycemia (low blood sugar) in diabetics at least two years old. It will be available in prefilled syringe and autoinjector (Hyp...